[go: up one dir, main page]

EA201600002A1 - Производные пролекарства замещенных триазолопиридинов - Google Patents

Производные пролекарства замещенных триазолопиридинов

Info

Publication number
EA201600002A1
EA201600002A1 EA201600002A EA201600002A EA201600002A1 EA 201600002 A1 EA201600002 A1 EA 201600002A1 EA 201600002 A EA201600002 A EA 201600002A EA 201600002 A EA201600002 A EA 201600002A EA 201600002 A1 EA201600002 A1 EA 201600002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
triazolopiridines
substituted
mps
diseases
Prior art date
Application number
EA201600002A
Other languages
English (en)
Inventor
Фолькер Шульце
Ханс-Георг Лерхен
Дональд Бирер
Антье Маргрет Венгнер
Герхард Зимайстер
Филип Линау
Урзула Кренц
Дирк Коземунд
Детлеф Штёкигт
Михаель Брюнинг
Ульрих Люкинг
Ильдико Теребези
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201600002A1 publication Critical patent/EA201600002A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным пролекарств ингибиторов Mps-1 киназы формулы (I), к способам их получения, а также к их применению для лечения и/или профилактики заболеваний.
EA201600002A 2013-06-11 2014-06-06 Производные пролекарства замещенных триазолопиридинов EA201600002A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Publications (1)

Publication Number Publication Date
EA201600002A1 true EA201600002A1 (ru) 2016-06-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600002A EA201600002A1 (ru) 2013-06-11 2014-06-06 Производные пролекарства замещенных триазолопиридинов

Country Status (35)

Country Link
US (1) US9586958B2 (ru)
EP (1) EP3008062B1 (ru)
JP (1) JP2016526534A (ru)
KR (1) KR20160019492A (ru)
CN (1) CN105377848A (ru)
AP (1) AP2015008898A0 (ru)
AR (1) AR096585A1 (ru)
AU (1) AU2014280356A1 (ru)
CA (1) CA2914745A1 (ru)
CL (1) CL2015003605A1 (ru)
CR (1) CR20150659A (ru)
CU (1) CU20150176A7 (ru)
DK (1) DK3008062T3 (ru)
DO (1) DOP2015000299A (ru)
EA (1) EA201600002A1 (ru)
ES (1) ES2626790T3 (ru)
HK (1) HK1221955A1 (ru)
HR (1) HRP20170717T1 (ru)
HU (1) HUE033131T2 (ru)
IL (1) IL242847A0 (ru)
LT (1) LT3008062T (ru)
MA (1) MA38654B1 (ru)
MX (1) MX2015017119A (ru)
NI (1) NI201500176A (ru)
PE (1) PE20160156A1 (ru)
PH (1) PH12015502746A1 (ru)
PL (1) PL3008062T3 (ru)
PT (1) PT3008062T (ru)
RS (1) RS56034B1 (ru)
SG (1) SG11201509858QA (ru)
SI (1) SI3008062T1 (ru)
TN (1) TN2015000545A1 (ru)
UY (1) UY35610A (ru)
WO (1) WO2014198647A2 (ru)
ZA (1) ZA201508868B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
MX384752B (es) * 2016-04-04 2025-03-14 Chemocentryx Inc ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
CA3241111A1 (en) * 2021-12-15 2023-06-22 Heidi Lane Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
ES2235331T3 (es) 1997-05-28 2005-07-01 Aventis Pharmaceuticals Inc Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck.
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
KR20090026288A (ko) 2006-05-31 2009-03-12 갈라파고스 엔.브이. 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
AR067562A1 (es) 2007-07-18 2009-10-14 Novartis Ag Compuestos heterociclicos inhibidores de kinasa
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
EP2212326A1 (en) 2007-08-23 2010-08-04 AstraZeneca AB 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
KR20100075881A (ko) 2007-08-31 2010-07-05 메르크 세로노 에스. 에이. 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20100086492A (ko) 2007-11-27 2010-07-30 셀좀 리미티드 Ｐｉ3ｋ 억제제로서의 아미노 트리아졸
AU2009260447B2 (en) 2008-05-30 2012-03-29 Amgen Inc. Inhibitors of PI3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
PE20120110A1 (es) 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2523955B1 (en) 2010-01-15 2014-07-16 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
AP3491A (en) 2011-04-21 2015-12-31 Bayer Ip Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
EP2825540B1 (en) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
MX2015000348A (es) * 2012-07-10 2015-04-14 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas.
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类
CA2914668A1 (en) * 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
MX2015017120A (es) * 2013-06-11 2016-10-05 Bayer Pharma AG Combinaciones para el tratamiento de cancer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis.

Also Published As

Publication number Publication date
CL2015003605A1 (es) 2016-06-24
US9586958B2 (en) 2017-03-07
WO2014198647A3 (en) 2015-02-05
PL3008062T3 (pl) 2017-08-31
HUE033131T2 (en) 2017-11-28
RS56034B1 (sr) 2017-09-29
DOP2015000299A (es) 2016-03-15
AP2015008898A0 (en) 2015-12-31
UY35610A (es) 2015-01-30
NI201500176A (es) 2016-01-06
ES2626790T3 (es) 2017-07-26
EP3008062B1 (en) 2017-04-05
PE20160156A1 (es) 2016-04-20
EP3008062A2 (en) 2016-04-20
JP2016526534A (ja) 2016-09-05
LT3008062T (lt) 2017-06-12
SG11201509858QA (en) 2015-12-30
AR096585A1 (es) 2016-01-20
CA2914745A1 (en) 2014-12-18
DK3008062T3 (en) 2017-06-12
CN105377848A (zh) 2016-03-02
WO2014198647A2 (en) 2014-12-18
HRP20170717T1 (hr) 2017-07-28
MX2015017119A (es) 2016-04-06
PH12015502746A1 (en) 2016-03-21
MA38654B1 (fr) 2018-11-30
IL242847A0 (en) 2016-02-01
CR20150659A (es) 2016-01-29
PT3008062T (pt) 2017-06-07
HK1221955A1 (zh) 2017-06-16
US20160207915A1 (en) 2016-07-21
SI3008062T1 (sl) 2017-06-30
AU2014280356A1 (en) 2015-12-24
TN2015000545A1 (en) 2017-04-06
ZA201508868B (en) 2017-08-30
KR20160019492A (ko) 2016-02-19
CU20150176A7 (es) 2016-05-30

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201590748A1 (ru) Противовирусные соединения против rsv
MX2015005015A (es) Inhibidores heteroarilo de pde4.
UA117958C2 (uk) Похідні хіноксаліну, корисні як модулятори кінази fgfr
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201690844A1 (ru) Ингибиторы gsk-3
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
EA201691141A1 (ru) Соединения против ccr6
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases